04:44 PM EST, 12/22/2025 (MT Newswires) -- Fulgent Genetics ( FLGT ) said late Monday that it will acquire Bako Diagnostics and StrataDx for $55.5 million, broadening its lab services platform and national reach.

The acquisitions add anatomic pathology, proprietary PCR tests, and a national client base to Fulgen as Bako and StrataDx are CLIA certified and CAP accredited, the company said.

The deal nearly doubles Fulgent's pathology sales team and strengthens its digital pathology and AI capabilities via the Eziopath system, it added.

The transaction is set to close in the first half of 2026 and will be financed using cash on hand.